This evaluation leads to the differentiation of (a) HR-positive, HER2-negative BC patients, (b) HR-positive, HER2-positive patients, (c) HR-negative, HER2-positive patients and (d) HR-negative and HER2-negative (triple negative BC, TNBC) patients [7]. The gene discussed is ERBB2; the disease is breast cancer.